Flerobuterol Explained

Class:β-Adrenergic receptor agonist
Cas Number:82101-10-8
Pubchem:71254
Chemspiderid:64385
Unii:F05RR5M463
Chembl:2106772
Synonyms:CRL-40827
Iupac Name:2-(tert-butylamino)-1-(2-fluorophenyl)ethanol
C:12
H:18
F:1
N:1
O:1
Smiles:CC(C)(C)NCC(C1=CC=CC=C1F)O
Stdinchi:1S/C12H18FNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3
Stdinchikey:XTJMTDZHCLBKFU-UHFFFAOYSA-N

Flerobuterol (; developmental code name CRL-40827) is a selective β-adrenergic receptor agonist related to salbutamol which was under development for the treatment of major depressive disorder but was never marketed.[1] [2] [3] It is an agonist of the β1-, β2-, and β3-adrenergic receptors.[4] The drug was under development in France by Cephalon and Lafon and reached phase 2 clinical trials prior to its development being discontinued. It was first described in the scientific literature by 1988 and its development was terminated in 2007.

Notes and References

  1. Web site: Flerobuterol . AdisInsight . Springer Nature Switzerland AG . 26 October 2011 . 27 September 2024.
  2. Bosker FJ, Westerink BH, Cremers TI, Gerrits M, van der Hart MG, Kuipers SD, van der Pompe G, ter Horst GJ, den Boer JA, Korf J . Future antidepressants: what is in the pipeline and what is missing? . CNS Drugs . 18 . 11 . 705–732 . 2004 . 15330686 . 10.2165/00023210-200418110-00002 .
  3. Chariot J, De La Tour J, Vaille C, Rozé C . Effects of CRL 40827 and salbutamol on exocrine pancreatic secretion in rats . European Journal of Pharmacology . 146 . 1 . 17–25 . January 1988 . 2895009 . 10.1016/0014-2999(88)90482-7 .
  4. Zini R, Morin D, Martin P, Puech AJ, Tillement JP . Interactions of flerobuterol, an antidepressant drug candidate, with beta adrenoceptors in the rat brain . The Journal of Pharmacology and Experimental Therapeutics . 259 . 1 . 414–422 . October 1991 . 1681091 .